🔎 Trials Near Me

መነሻ › አኩት ማይሎይድ ሊውኬሚያ › Texas › Houston

በHouston፣ TX ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 85 ጥናቶች በHouston እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT07581002

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናትጤናማ ተሳታዮች ይቀበላሉ
  • UT MD Anderson Cancer Center, Houston
እድሜ ከ40 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Texas Children's Hospital, Houston
እድሜ ከ0 እስከ 38 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06131801

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • University of Texas MD Anderson Cancer Center, Houston
እድሜ ከ12 እስከ 78 · ሁሉም ጾታዎች · የተሻሻለው በ29 ሴፕቴ 2026 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Houston Methodist Cancer Center, Houston
  • MD Anderson Cancer Center, Houston
  • The University of Texas Health Science Center at Houston, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT05564390

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT03629171

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06548230

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Clinical Trial Site, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT07211958

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2026 · NCT03661307

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2ጤናማ ተሳታዮች ይቀበላሉ
  • M D Anderson Cancer Center, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ሴፕቴ 2026 · NCT05360160

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas M. D. Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT06769490

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT03214562

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT06284486

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • M D Anderson Cancer Center, Houston
እድሜ 1 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT03630991

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT06786533

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Texas Children's Hospital, Houston
  • The Methodist Hospital, Houston
እስከ እድሜ 75 · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT06345027

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ሴፕቴ 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT04996875

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Md Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT04771130

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06616636

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሴፕቴ 2026 · NCT06969430

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT05010122

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT03383575

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ ከ2 እስከ 18 · ሁሉም ጾታዎች · የተሻሻለው በ4 ሴፕቴ 2026 · NCT06191978

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT04588922

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ ከ18 እስከ 85 · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT06834282

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04493164

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT06533761

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • The University of Texas M. D. Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT06811233

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • UT MD Anderson Cancer Center, Houston
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Texas Children's Hospital, Houston
29 Days – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT05183035

UPDATE AML: UPdated Disease Monitoring And Treatment for Enhanced Outcomes for Pediatric AML

ተሳታዮችን በመፈለግ ላይየመጀመሪያ ደረጃ 1
  • Texas Children's Cancer and Hematology Center, Houston
1 Month – 30 Years · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT07059975

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • University of Texas, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788

Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

ተሳታዮችን በመፈለግ ላይደረጃ 2/3ጤናማ ተሳታዮች ይቀበላሉ
  • M D Anderson Cancer Center, Houston
እድሜ ከ18 እስከ 70 · ሁሉም ጾታዎች · የተሻሻለው በ11 ኦገስ 2026 · NCT04708054

Phase I Study of HC-7366 for Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ኦገስ 2026 · NCT06285890

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ ከ12 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ7 ኦገስ 2026 · NCT05092451

Personalized NK Cell Therapy in CBT

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ ከ15 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ30 ጁላይ 2026 · NCT02727803

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Research Site, Houston
እድሜ 16 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ጁላይ 2026 · NCT07155226

Decitabine Alone or in Combination With Venetoclax, Gilteritinib, Enasidenib, or Ivosidenib as Maintenance Therapy for the Treatment of Acute Myeloid Leukemia in Remission

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጁላይ 2026 · NCT05010772

Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Texas MD Anderson Cancer Center, Houston
እድሜ 60 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጁላይ 2026 · NCT01515527

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • M.D. Anderson Cancer Center, Houston
  • Texas Children's Hospital - Baylor Medical Center, Houston
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

A Study of Revumenib and Mezigdomide in People With Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center (Data Collection Only), Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ጁን 2026 · NCT07356154

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT03113643

BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁን 2026 · NCT05768932

Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ጁን 2026 · NCT02074839

A Phase I Study Investigating the Combination of the Menin Inhibitor Ziftomenib With Venetoclax and Gemtuzumab in Pediatric Patients With Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ ከ3 እስከ 21 · ሁሉም ጾታዎች · የተሻሻለው በ12 ጁን 2026 · NCT06448013

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ጁን 2026 · NCT04047641

A Phase Ib Trial of Azacitidine, Venetoclax and Allogeneic NK Cells for Acute Myeloid Leukemia (ADVENT-AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • M.D. Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ12 ጁን 2026 · NCT05834244

Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients With Previously Untreated Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 50 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ8 ጁን 2026 · NCT03586609

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Renal Impairment

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሜይ 2026 · NCT04953897

Study to Evaluate the Pharmacokinetics and Safety of Oral Decitabine and Cedazuridine in Cancer Patients With Hepatic Impairment

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ሜይ 2026 · NCT04953910

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሜይ 2026 · NCT03589729

Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • M D Anderson Cancer Center, Houston
እድሜ ከ18 እስከ 65 · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT02115295

Decitabine/Cedazuridine and Venetoclax in Combination With Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ሜይ 2026 · NCT04774393

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317

PET/MRI, 18F-FDG PET/CT and Whole Body MRI in Finding Extramedullary Myeloid Leukemia in Patients With Newly Diagnosed Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ኤፕሪ 2026 · NCT02390635

Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • M D Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ኤፕሪ 2026 · NCT04140487

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ኤፕሪ 2026 · NCT05732103

Safety and Proof-of-Concept Study of RPT1G in Adults With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndromes

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ማርች 2026 · NCT07107126

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MDACC, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ማርች 2026 · NCT04988555

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • MD Anderson, Houston
እድሜ ከ18 እስከ 66 · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06859424

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ማርች 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT06950034

CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ጃንዩ 2026 · NCT05143996

Clinical Study of ARD103 CAR-T Therapy for Patients With R/R AML or MDS

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ዲሴም 2025 · NCT06680752

Danvatirsen Monotherapy Followed by Combination With Venetoclax in Relapsed/Refractory MDS & AML

ተሳታዮችን በመፈለግ ላይደረጃ 1ጤናማ ተሳታዮች ይቀበላሉ
  • M.D. Anderson Cancer Center, Department of Leukemia, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ኖቬም 2025 · NCT05986240

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ31 ኦክቶ 2025 · NCT06549790

AB8939 in Patients With Relapsed/Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ኦክቶ 2025 · NCT05211570

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas M.D. Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ሴፕቴ 2025 · NCT06501196

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ11 ሜይ 2025 · NCT06634394

Study of REM-422 in Patients With AML or Higher Risk MDS

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ኤፕሪ 2025 · NCT06297941

Study of Oral PCLX-001 in R/R Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Centre, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ማርች 2025 · NCT06613217

A Clinical Trial of BP1002 in Patients With Refractory/Relapsed Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ10 ማርች 2025 · NCT05190471

Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • University of Texas M.D. Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ማርች 2025 · NCT02781883

Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ኖቬም 2024 · NCT06034275

A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • The University of Texas MD Anderson Cancer Center, Houston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ማርች 2024 · NCT04243785

በሌሎች ከተሞች ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ጥናቶች

በHouston ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።